Immunocore Holdings PLC
NASDAQ:IMCR

Watchlist Manager
Immunocore Holdings PLC Logo
Immunocore Holdings PLC
NASDAQ:IMCR
Watchlist
Price: 28.9 USD 2.7%
Market Cap: 1.4B USD
Have any thoughts about
Immunocore Holdings PLC?
Write Note

Immunocore Holdings PLC
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Immunocore Holdings PLC
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Immunocore Holdings PLC
NASDAQ:IMCR
Operating Expenses
-ÂŁ308m
CAGR 3-Years
-37%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Operating Expenses
-$178.1m
CAGR 3-Years
-157%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Operating Expenses
-ÂŁ167.1m
CAGR 3-Years
-91%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Operating Expenses
-$177.2m
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Operating Expenses
-$233.4m
CAGR 3-Years
-45%
CAGR 5-Years
-43%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Operating Expenses
-ÂŁ614.6m
CAGR 3-Years
-6%
CAGR 5-Years
-36%
CAGR 10-Years
-6%
No Stocks Found

Immunocore Holdings PLC
Glance View

Market Cap
1.4B USD
Industry
Biotechnology

Immunocore Holdings PLC stands as a pioneering force in the field of immunotherapy, leveraging its proprietary T-cell receptor (TCR) technology to transform the treatment landscape for various severe diseases. Rooted in cutting-edge science, the British biotech firm develops novel therapeutic agents targeting cancer, infectious diseases, and autoimmune conditions. Its leading platform technology, known as ImmTACs (Immune Mobilizing Monoclonal TCRs Against Cancer), ingeniously redirects T-cells—an integral component of the immune system—to recognize and obliterate cancerous cells in a highly targeted manner. By focusing on ultra-specific peptide-major histocompatibility complex (pMHC) targets, Immunocore meticulously designs its therapies to minimize off-target effects and maximize efficacy in tackling conditions that have eluded traditional treatment methods. Financially, Immunocore operates through a strategic blend of commercial and collaborative partnerships, alongside its independent pipeline advancements. It generates revenue by licensing its innovative technology to larger pharmaceutical entities that seek to add cutting-edge biologics to their portfolios. Additionally, milestone and royalty payments from collaborative research initiatives contribute significantly to its financial foundation. These partnerships not only bolster Immunocore's revenue streams but also accelerate its research and development efforts, enabling a faster path to market for its groundbreaking treatments. As a result, the company stands at the confluence of science and commerce, channeling its unique TCR technology to make meaningful strides in medical innovation and patient care.

IMCR Intrinsic Value
113.04 USD
Undervaluation 74%
Intrinsic Value
Price

See Also

What is Immunocore Holdings PLC's Operating Expenses?
Operating Expenses
-308m GBP

Based on the financial report for Dec 31, 2023, Immunocore Holdings PLC's Operating Expenses amounts to -308m GBP.

What is Immunocore Holdings PLC's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-21%

Over the last year, the Operating Expenses growth was -67%. The average annual Operating Expenses growth rates for Immunocore Holdings PLC have been -37% over the past three years , -21% over the past five years .

Back to Top